Clinical Trials Search
Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
The purpose of this study is to determine the safety, tolerability and feasibility of an adenosine A2a receptor antagonist (PBF-509) during a phase I dose escalation trial in advanced or metastatic non-small cell lung cancer (NSCLC) patients.
Primary Objective: To determine the safety, tolerability and feasibility of PBF-509 during a phase I dose escalation trial. Secondary Objectives: 1. Determine the pharmacokinetic profile of PBF-509. 2. Determine the safety profile of PBF-509. 3. Response rate and duration, and survival.
PBF-509 (); PDR001 (Spartalizumab)